Can everyday lifestyle choices really protect your memory? Dr. Laura Baker, professor at Wake Forest University School of Medicine, shares insights from the groundbreaking U.S. POINTER trial—the largest study of its kind exploring how lifestyle changes impact brain health. She breaks down how factors like exercise, nutrition, cognitive engagement, and social connection work together, and what practical steps you can take to reduce your risk of dementia.

For a deeper dive into lifestyle and Alzheimer’s risk, watch our full conversation with Dr. Baker, part of the Zoom In on Dementia and Alzheimer’s series.

Support for Let’s Talk Alzheimer’s is provided by sponsors Lilly, Biogen, Eisai, and Genentech.

Let’s Talk Alzheimer’s is presented by Alzheimer’s Disease Research, a BrightFocus Foundation program. We fund exceptional research across the globe to support the development of cutting-edge treatments, risk reduction strategies, and ultimately a cure for this mind-stealing disease. Visit brightfocus.org to learn more and get involved.

Detecting subtle changes in memory or thinking can be unsettling, but understanding what’s behind those changes can lead to critical early diagnosis—or even rule out Alzheimer’s altogether. In this episode, behavioral neurologist Dr. Sharon Cohen, medical director at Toronto Memory Program, explains the early signs and symptoms of Alzheimer’s disease, medical conditions that can mimic dementia, and how to start a conversation with your doctor.

To go deeper, watch our full conversation with Dr. Cohen, part of the Zoom In on Dementia and Alzheimer’s series.

Support for Let’s Talk Alzheimer’s is provided by sponsors Lilly, Biogen, Eisai, and Genentech.

Let’s Talk Alzheimer’s is presented by Alzheimer’s Disease Research, a BrightFocus Foundation program. We fund exceptional research across the globe to support the development of cutting-edge treatments, risk reduction strategies, and ultimately a cure for this mind-stealing disease. Visit brightfocus.org to learn more and get involved.

Just three years ago, there were no FDA-approved treatments that targeted the underlying causes of Alzheimer’s—only medications that modified symptoms. Today, two FDA-approved therapies—Leqembi (lecanemab) and Kisunla (donanemab)—clear amyloid protein from the brain, targeting a potential cause of the disease. Dr. Armen J. Moughamian, a neurologist and medical director of the Ray Dolby Brain Health Center at Sutter Health, joins this episode to answer common questions about what these new therapies can realistically do, including effectiveness, safety, eligibility, infusion logistics, cost, and access.

To learn more, watch our full conversation with Dr. Moughamian, part of the Zoom In on Dementia and Alzheimer’s series.

Support for Let’s Talk Alzheimer’s is provided by sponsors Lilly, Biogen, Eisai, and Genentech.

Let’s Talk Alzheimer’s is presented by Alzheimer’s Disease Research, a BrightFocus Foundation program. We fund exceptional research across the globe to support the development of cutting-edge treatments, risk reduction strategies, and ultimately a cure for this mind-stealing disease. Visit brightfocus.org to learn more and get involved.